VenatoRx Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-06-04
- Employees
- 51
- Market Cap
- -
- Website
- http://www.venatorx.com
Clinical Trials
24
Active:7
Completed:15
Trial Phases
3 Phases
Phase 1:19
Phase 3:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 1
19 (86.4%)Phase 3
2 (9.1%)Not Applicable
1 (4.5%)Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
Phase 1
Active, not recruiting
- Conditions
- Healthy VolunteerPharmacokineticsSafetyDrug-Drug Interaction (DDI)FDC
- Interventions
- Drug: Ceftibuten-ledaborbactam etzadroxil
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT06733675
- Locations
- 🇺🇸
ICON, Clinical Research Phase I Unit, Lenexa, Kansas, United States
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
Phase 1
Completed
- Conditions
- PharmacokineticsHealthy Volunteers
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT06665555
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Phase 3
Withdrawn
- Conditions
- Ventilator-associated PneumoniaHospital-acquired Pneumonia
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 316
- Registration Number
- NCT06168734
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05527834
- Locations
- 🇺🇸
ICON Plc., Lenexa, Kansas, United States
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05488678
- Locations
- 🇺🇸
Advanced Pharma, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Nucleus Network, Saint Paul, Minnesota, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found